IMO, CMTR is a company with a long (relatively) history of troubles: multiple layoffs, management changes, declining stock price, little or no growth, etc. At these prices it might be worth gambling. But, again IMO, the investment would come under the heading of "wishful thinking".
By the way, last weeks filing was the annual report. Some highlights:
Products under development include tests for glycosylated hemoglobin (for diabetics), menopause, osteoporosis and prostate cancer.
The application for home HIV test was withdrawn from the FDA.
The section entitled "RISKS" takes up >6 of the 32 pages of the report.
Product revenues: 1997 - $2,819,000, 1996 - $2,463,000.
Accumulated deficit: 1997 - $41,503,000, 1996 - $36,308,000
Total Stockholders' equity: 1997 - $2,208,000, 1996 -- $5,030,000
If you want a copy, you can call CMTR at (408) 773 - 8156. |
